Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $72.45 million. The enterprise value is -$56.91 million.
| Market Cap | 72.45M |
| Enterprise Value | -56.91M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 61.92 million shares outstanding. The number of shares has increased by 0.98% in one year.
| Current Share Class | 61.92M |
| Shares Outstanding | 61.92M |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 69.86% |
| Float | 55.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 19.15 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.90, with a Debt / Equity ratio of 0.20.
| Current Ratio | 9.90 |
| Quick Ratio | 9.64 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -95.88 |
Financial Efficiency
Return on equity (ROE) is -50.29% and return on invested capital (ROIC) is -24.99%.
| Return on Equity (ROE) | -50.29% |
| Return on Assets (ROA) | -23.27% |
| Return on Invested Capital (ROIC) | -24.99% |
| Return on Capital Employed (ROCE) | -52.58% |
| Weighted Average Cost of Capital (WACC) | 8.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.16% in the last 52 weeks. The beta is 1.27, so PLRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -25.16% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 66.58 |
| Average Volume (20 Days) | 404,372 |
Short Selling Information
The latest short interest is 2.81 million, so 4.53% of the outstanding shares have been sold short.
| Short Interest | 2.81M |
| Short Previous Month | 2.82M |
| Short % of Shares Out | 4.53% |
| Short % of Float | 5.10% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -91.18M |
| Pretax Income | -92.29M |
| Net Income | -92.29M |
| EBITDA | -89.87M |
| EBIT | -91.18M |
| Earnings Per Share (EPS) | -$1.50 |
Balance Sheet
The company has $158.10 million in cash and $28.74 million in debt, with a net cash position of $129.36 million or $2.09 per share.
| Cash & Cash Equivalents | 158.10M |
| Total Debt | 28.74M |
| Net Cash | 129.36M |
| Net Cash Per Share | $2.09 |
| Equity (Book Value) | 146.93M |
| Book Value Per Share | 2.37 |
| Working Capital | 146.66M |
Cash Flow
| Operating Cash Flow | -70.90M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.31M |
| Net Borrowing | -32.27M |
| Free Cash Flow | -70.90M |
| FCF Per Share | -$1.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.98% |
| Shareholder Yield | -0.98% |
| Earnings Yield | -126.84% |
| FCF Yield | -97.44% |
Analyst Forecast
The average price target for PLRX is $2.50, which is 113.68% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.50 |
| Price Target Difference | 113.68% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |